Literature DB >> 32345064

Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking.

Lorenzo Guglielmetti1,2,3, Marcus Low4,5,6, Lindsay McKenna5,7.   

Abstract

Entities:  

Keywords:  EMA; FDA; MDR-TB; Tuberculosis; WHO; XDR-TB; clinical trial; drug resistance; new drug

Mesh:

Substances:

Year:  2020        PMID: 32345064     DOI: 10.1080/14787210.2020.1756776

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


× No keyword cloud information.
  1 in total

1.  Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.

Authors:  Allison LaHood; Rifat Rahman; Lindsay McKenna; Mike Frick; Carole D Mitnick
Journal:  PLoS One       Date:  2022-07-25       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.